IMUX Valuation
Immunic Inc
$
0.950
- Overview
- Forecast
- Valuation
- Earnings
IMUX Relative Valuation
IMUX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMUX is overvalued; if below, it's undervalued.
Historical Valuation
Immunic Inc (IMUX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.34. The fair price of Immunic Inc (IMUX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.95
Fair
-1.76
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Immunic Inc. (IMUX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 10.53. The thresholds are as follows: Strongly Undervalued below -148.05, Undervalued between -148.05 and -68.76, Fairly Valued between 89.83 and -68.76, Overvalued between 89.83 and 169.12, and Strongly Overvalued above 169.12. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.33
EV/EBIT
Immunic Inc. (IMUX) has a current EV/EBIT of -0.33. The 5-year average EV/EBIT is -1.14. The thresholds are as follows: Strongly Undervalued below -4.03, Undervalued between -4.03 and -2.58, Fairly Valued between 0.31 and -2.58, Overvalued between 0.31 and 1.76, and Strongly Overvalued above 1.76. The current Forward EV/EBIT of -0.33 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Immunic Inc. (IMUX) has a current PS of 0.00. The 5-year average PS is 1208.68. The thresholds are as follows: Strongly Undervalued below -5877.09, Undervalued between -5877.09 and -2334.21, Fairly Valued between 4751.57 and -2334.21, Overvalued between 4751.57 and 8294.46, and Strongly Overvalued above 8294.46. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.89
P/OCF
Immunic Inc. (IMUX) has a current P/OCF of -0.89. The 5-year average P/OCF is -7.49. The thresholds are as follows: Strongly Undervalued below -53.87, Undervalued between -53.87 and -30.68, Fairly Valued between 15.70 and -30.68, Overvalued between 15.70 and 38.90, and Strongly Overvalued above 38.90. The current Forward P/OCF of -0.89 falls within the Historic Trend Line -Fairly Valued range.
-0.78
P/FCF
Immunic Inc. (IMUX) has a current P/FCF of -0.78. The 5-year average P/FCF is -1.25. The thresholds are as follows: Strongly Undervalued below -6.51, Undervalued between -6.51 and -3.88, Fairly Valued between 1.38 and -3.88, Overvalued between 1.38 and 4.01, and Strongly Overvalued above 4.01. The current Forward P/FCF of -0.78 falls within the Historic Trend Line -Fairly Valued range.
Immunic Inc (IMUX) has a current Price-to-Book (P/B) ratio of 2.68. Compared to its 3-year average P/B ratio of 0.56 , the current P/B ratio is approximately 376.24% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about 136.60% higher. Immunic Inc (IMUX) has a Forward Free Cash Flow (FCF) yield of approximately -100.28%. Compared to its 3-year average FCF yield of -85.66%, the current FCF yield is approximately 17.07% lower. Relative to its 5-year average FCF yield of -62.23% , the current FCF yield is about 61.15% lower.
2.75
P/B
Median3y
0.56
Median5y
1.13
-99.47
FCF Yield
Median3y
-85.66
Median5y
-62.23
Competitors Valuation Multiple
The average P/S ratio for IMUX's competitors is 696.19, providing a benchmark for relative valuation. Immunic Inc Corp (IMUX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IMUX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IMUX in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Immunic Inc (IMUX) currently overvalued or undervalued?
Immunic Inc (IMUX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.34. The fair price of Immunic Inc (IMUX) is between to according to relative valuation methord.
What is Immunic Inc (IMUX) fair value?
How does IMUX's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunic Inc (IMUX) as of Aug 23 2025?
What is the current FCF Yield for Immunic Inc (IMUX) as of Aug 23 2025?
What is the current Forward P/E ratio for Immunic Inc (IMUX) as of Aug 23 2025?